Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Caladrius Biosciences, Inc. M&A Partner Cend Therapeutics Announces First Patient Treated In Phase 2b Trial Of CEND-1 Led By Australasian Gastro-Intestinal Trials Group

Author: Bill Haddad | June 09, 2022 08:09am

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. ("Cend") today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend's lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma.
 

Posted In: CLBS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist